Navigation Links
ThromboGenics Establishes Level 1 ADR Program for US Investors
Date:9/29/2013

New York, NY 10005

In the U.S.: (866) JPM-ADRS  

Outside the U.S.: (+1 866  576-2377)

Or visit J.P. Morgan Depositary Receipts Services at http://www.adr.com.

About ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company's lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013.  

ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of JETREA® outside the United States. Under this agreement, ThromboGenics could receive up to a total of €375 million in up-front and milestone payments. It will receive significant royalties from Alcon's net sales of JETREA®. ThromboGenics and Alcon intend to share the costs equally of developing JETREA® for a number of new vitreoretinal indications.

In Europe, JETREA® is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. Alcon has launched JETREA® in the UK, Germany, Denmark, Norway, Finland and Sweden.  

ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor), also referred to as TB-403.

ThromboGenics is headquartered in Leuven, Belgium, and has-offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction.  No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.


'/>"/>
SOURCE ThromboGenics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Pittcon Establishes a Collaborative Program Resource Team for 2014
2. Alacrita Establishes U.S. Headquarters in Boston Area
3. Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board
4. FDA Establishes New Product Codes for Interbody Devices With Integrated Fixation
5. RURO Adds Critical Level Monitoring Functionality to its Transgenic Animal Management Software ezColony
6. Novelda Appoints Alf-Egil Bogen as Chief Executive Officer to Lead the Company to the Next Level
7. Desktop printing at the nano level
8. Low Blood DHA Levels Linked to Decreased Reading Ability and Memory Performance in Children
9. New Study Reveals that PEEK Polymer Spinal Cage Is Superior to Titanium in Surgical Treatment of Multilevel Cervical Spondylotic Myelopathy
10. Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference
11. IntraMed Diagnostics Announces Two Senior-Level Additions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... , ... FireflySci Inc. is a go-getter type of company that continues to ... two main factors. The first is the amazing customer service that the FireflySci ... all around the world. , 2016 was a tremendous sales year for FFS and ...
(Date:1/19/2017)... , Jan. 18, 2017 BD (Becton, Dickinson and ... announced today that it will host a live webcast of its ... p.m. (ET). The webcast can be accessed from ... for replay through Tuesday, January 31, 2017. ... About BD BD is a ...
(Date:1/18/2017)... --  Parent Project Muscular Dystrophy (PPMD) , a nonprofit ... dystrophy (Duchenne) , today announced a $600,000 grant to ... (NJIT) and Talem Technologies (Talem) as part of the ... assist people living with Duchenne. PPMD is funding a ... computer, software, a force sensor and a motor – ...
(Date:1/18/2017)... ... January 18, 2017 , ... MYOLYN, which creates medical technology ... a 510(k) to the FDA, requesting clearance of the MyoCycle Home and the ... technology. , The submission marks a major milestone for the technology startup. ...
Breaking Biology Technology:
(Date:12/16/2016)... , Dec. 16, 2016 The global wearable medical device ... billion by 2021 from USD 5.31 billion in 2016, at a ... ... driven by technological advancements in medical devices, launch of a growing ... for wireless connectivity among healthcare providers, and increasing focus on physical ...
(Date:12/15/2016)... 2016  There is much more to innovative access ... engine. Continental will demonstrate the intelligence of today,s solutions ... . Through the combination of the keyless entry and ... elements, the international technology company is opening up new ... "The integration of biometric elements brings our ...
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition ... Service, Application Area, End User, And Region - Global Forecast to 2021", published ... in 2016 to USD 36.07 Billion by 2021, at a Compound Annual Growth ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):